English | 简体中文 | 繁體中文 | 한국어
 All Press Releases
 Medicine BioTech
The Biotech Landscape Webinar: Market Trends, Priorities, Predictions, and Pathways to FDA Approval
Oct 17, 2022 11:00 HKT
医思健康料23上半财年销售额创新高至不少于18亿港元 按年升不少于17%
Oct 17, 2022 08:50 HKT
醫思健康料23上半財年銷售額創新高至不少於18億港元 按年升不少於17%
Oct 17, 2022 08:49 HKT
EC Healthcare expects a record-high semi-annual sales volume in first half of FY23 of no less than HK$1.8 billion, Represents no less than 17% Y-o-Y increase
Oct 17, 2022 08:48 HKT
佈局海外 金活醫藥集團完成收購法國Innopharm公司
Oct 14, 2022 23:07 HKT
노보텍 인디아, ‘글로벌 근로 표준 당국’으로부터 “2022년 여성을 위한 최고의 직장”으로 선정
Oct 14, 2022 11:00 HKT
Essex Biotechnology Secures Exclusive Rights and Interests in SkQ1 for Ophthalmology from Mitotech
Oct 13, 2022 22:40 HKT
亿胜生物成功从Mitotech获得SkQ1眼科领域全球独家权益
Oct 13, 2022 22:34 HKT
億勝生物成功從Mitotech獲得SkQ1眼科領域全球獨家權益
Oct 13, 2022 22:33 HKT
多宁生物冲刺港交所:领跑生物工艺行业 客户高粘性构筑长期韧性
Oct 12, 2022 14:34 HKT
多寧生物衝刺港交所:領跑生物工藝行業 客戶高粘性構築長期韌性
Oct 12, 2022 14:33 HKT
Malaysian Genomics Signs Agreement with National Institutes of Health to Explore Research Opportunities
Oct 12, 2022 13:00 HKT
Novotech India 被全球工作标准局评为“2022 年女性最佳工作场所”
Oct 12, 2022 11:00 HKT
Novotech India 被全球工作標準局評為“2022 年女性最佳工作場所”
Oct 12, 2022 11:00 HKT
Novotech India Recognised as "Best Workplaces for Women 2022" by Global Work Standards Authority
Oct 12, 2022 09:00 HKT
노보텍, 스크립 어워드 최우수 풀 서비스 CRO결선 진출자로 선정
Oct 11, 2022 10:00 HKT
Olympus EU-ME3 Ultrasound Processor, Delivers Higher Resolution Images for Endoscopic Ultrasound
Oct 10, 2022 14:00 HKT
华领医药全球首创新药葡萄糖激酶激活剂华堂宁(R)获批上市 有望拓展中国2型糖尿病治疗新格局
Oct 10, 2022 09:02 HKT
華領醫藥全球首創新藥葡萄糖激酶激活劑華堂寧(R)獲批上市 有望拓展中國2型糖尿病治療新格局
Oct 10, 2022 09:01 HKT
Hua Medicine's Innovative First-In-Class Glucokinase Activator (GKA) HuaTangNing Is Approved, New Type 2 Diabetes Treatment Paradigm to Begin in China
Oct 10, 2022 09:00 HKT
<< Previous  Next >>
Copyright © 2026 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: